VIKAS KUNDRA to Xenograft Model Antitumor Assays
This is a "connection" page, showing publications VIKAS KUNDRA has written about Xenograft Model Antitumor Assays.
Connection Strength
0.193
-
Tumor T1 Relaxation Time for Assessing Response to Bevacizumab Anti-Angiogenic Therapy in a Mouse Ovarian Cancer Model. PLoS One. 2015; 10(6):e0131095.
Score: 0.071
-
The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development. Clin Cancer Res. 2020 09 15; 26(18):4933-4946.
Score: 0.025
-
Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. Sci Transl Med. 2014 Sep 03; 6(252):252ra122.
Score: 0.017
-
Effect of transforming growth factor beta (TGF-?) receptor I kinase inhibitor on prostate cancer bone growth. Bone. 2012 Mar; 50(3):695-703.
Score: 0.014
-
Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol Cancer Ther. 2011 Dec; 10(12):2350-62.
Score: 0.014
-
A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res. 2008 Jan 01; 68(1):206-15.
Score: 0.011
-
Pharmacodynamic markers of perifosine efficacy. Clin Cancer Res. 2007 Dec 15; 13(24):7421-31.
Score: 0.011
-
Antitumor and antivascular effects of AVE8062 in ovarian carcinoma. Cancer Res. 2007 Oct 01; 67(19):9337-45.
Score: 0.010
-
Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts. Neoplasia. 2007 Jun; 9(6):479-86.
Score: 0.010
-
The 3p21.3 tumor suppressor NPRL2 plays an important role in cisplatin-induced resistance in human non-small-cell lung cancer cells. Cancer Res. 2006 Oct 01; 66(19):9682-90.
Score: 0.010